| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | 0.036 | 0.5 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | -0.019 | 0.5 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.032 | 0.5 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | -0.024 | 0.5 |